Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 26, 2020
In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN...
-
Nov 19, 2020
Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa® will benefit from Fresenius Kabi’s...
Nov 19, 2020- Reduction in number of attacks is leading factor when evaluating prophylactic therapyKING OF PRUSSIA, Pa. 19 Nov 2020 CSL Behring, a global biotherapeutics leader, today announced survey results showing that a vast majority of HAE patients (94%) say it’s important their...
-
Nov 16, 2020
16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...
-
Nov 16, 2020- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia
KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. 16 Nov 2020 Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting...
-
Nov 13, 2020
Ferinject® significantly reduced the incidence of heart failure hospitalizations in patients with iron deficiency after acute heart failure Results of the AFFIRM-AHF trial support the use of...
-
Nov 10, 2020Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
KING OF PRUSSIA, Pa. 10 Nov 2020 Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA)...
-
Nov 9, 2020
Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a...
-
Nov 8, 2020
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...